Navigation Links
Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
Date:8/22/2014

La Jolla, CA Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc. combats three types of human papillomavirus, including the two that cause 70 percent of all cervical cancer.

When tested in several cultured human cell models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according to Louise T. Chow, Ph.D. and Thomas Broker, Ph.D., who presented the findings at the Seattle conference. The National Institute of Allergy and Infectious Diseases in the National Institutes of Health funded Chow's work at the University of Alabama, Birmingham.

"HTI-1968 is potent and selective, inhibiting the growth of these high-risk HPV types. Dr. Chow's findings, though early stage, offer hope to millions of women infected by one of these high-risk HPV types, including two that are responsible for 70 percent of cervical cancer cases," said Hera Therapeutics CEO Karl Hostetler, M.D.. Currently surgery is the only therapy available to women who have persistent infection with these types of HPV and show signs of abnormal cells.

Hera Therapeutics is developing a topical, non-surgical approach to treat HPV, which could alter the standard of care while preserving structural integrity of the cervix.

Approximately 96 million people worldwide, men and women, are infected with HPV-16 or HPV-18, according to the Centers for Disease Control. Almost 4,000 women in the U.S. die from invasive cervical cancer each year, according to the CDC.

While cervical cancer vaccines prevent infection from the disease, they are not approved by the FDA for marketing to people over 26-years-old and have not demonstrated efficacy in people already infected with the HPV virus.


'/>"/>
Contact: Terri Somers, Somers Media
terri@somersmedia.com
619-991-2369
Somers Media
Source:Eurekalert

Page: 1

Related biology news :

1. Researchers develop models to study polyelectrolytes, including DNA and RNA
2. Lyme disease risk is year-round in Northwest California, according to new study
3. Recovery reversal seen in Oregon study of returning concussed athletes
4. Study of African dust transport to South America reveals air quality impacts
5. Fish study links brain size to parental duties
6. Climate change will threaten fish by drying out Southwest US streams, study predicts
7. Oregon team to study impacts of climate change on pesky forest insect
8. Study: Worlds primary forests on the brink
9. IU study examines how genes, gender and environment influence substance abuse
10. Scientists study talking turtles in Brazilian Amazon
11. NSAIDs benefit overweight breast cancer patients, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced today the ... Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at Andrews Memorial ... physician suffering from degenerative disc disease with radiculomyelopathy, as a result of degenerative ...
(Date:2/16/2017)... 2017  Rhythm, a biopharmaceutical company developing ... result in life-threatening metabolic disorders, today announced ... round of financing with existing investors including ... Enterprise Associates, Pfizer Venture Investments, Third Rock ... fund. Rhythm will use the proceeds to ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... extended its industry leading Biochemistry Services specifically targeting the rapidly growing needs ... methods for the biochemical and biosimilar characterization , product-related impurity characterization, ...
Breaking Biology Technology: